Search published articles


Showing 2 results for Sabbaghi

Maral Rostami Chayjan, Marjan Sabbaghian, Mehdi Alikhani, Fazel Sahraneshin Samani , Reza Salman Yazdi , Seyed Navid Almadani, Anahita Mohseni Mehbodi,
Volume 17, Issue 5 (8-2014)
Abstract

Background: Human &beta-defensin 126 (12kDa) is a small cationic glycoprotein that is highly rich of cysteine. DEFB126 gene is located on the subtelomeric end of 20p1.3 in human. High expression of this protein is reported in epididymis. This polypeptide coats the plasma membrane of sperm during epididy‌mal transit. It is likely that &beta -defensin 126 might have role in unexplained male infertility since it involves in sperm maturation and capacitation. The current research designed to investigate if there is relation between &beta-defensin 126 gene mutation and unexplained male infertility.

Materials and Methods: In this case-control study we followed a two cytosine nucleotides deletion of &beta-defensin 126 gene in 35 Iranian men with unexplained infertility and 40 fertile men with normal spermogeram as control group. Standard PCR, SSCP(Single strand conformational polymorphism), and sequencing were used to detect genetic alteration of &beta-defensin 126. ELISA was performed for the assessment of the protein expression on sperm cells.

Results: Analysis of genetic data revealed 28.6% homozygote deletion in unexplained infertile men while this deletion was detected in 7.5% of controls. The deletion frequency was statistically higher in infertile patients than normal control group (p<0.05). The protein expression was less in men with del/del genotype compare to the other genotypes (p<0.005).

Conclusion: Our study shows that this common sequence variation of &beta-defensin 126 takes part in impairment of male reproductive function. Consequently, men with the del/del genotype are significantly less fertile than men who carry the wild type allele.


Ailar Sabbaghi, Mohsen Zargar, Amir Ghaemi, Farahnaz Motamedi-Sedeh, Mohammad Reza Zolfaghari,
Volume 22, Issue 4 (9-2019)
Abstract

Background and Aim We need the next-generation of whole-inactivated influenza vaccines to create stronger cross-protection against different influenza subtypes. This research aimed to apply the inactivation process of the influenza virus through gamma radiation as a candidate for the development of whole-inactivated vaccines.
Methods and Materials The influenza virus strain A/PR/8/34 (A/Puerto Rico/8/34 [H1N1]) was propagated in Madin-Darby Canine Kidney (MDCK) epithelial cells. After ultrafiltration, the virus infectivity titer was calculated by 50% Tissue Culture Infectious Dose (TCID 50%) method based on the Karber formula. Alternatively, the gamma cell-220 was applied for virus inactivation via gamma rays. The D10 value factor and optimum dose of virus inactivation were calculated based on the dose/survival curve and the initial viral titer. In addition, antigenic properties of irradiated viruses compared to un-irradiated viruses and complete inactivation of the irradiated samples with optimum dose were also evaluated by hemagglutination assay and safety test, respectively.
Ethical Considerations The Research Ethics Committee of Islamic Azad University, Tehran Medical Branch, Iran approved this study (Code: IR.IAU.TMU.REC.1397.309).
Results According to the concentrated virus titer (TCID50: 105.75/ml) and dose/survival curve, the D10 value factor and optimum dose of virus inactivation were calculated at 4.878 and 28.048 kGy, respectively. On the other hand, owing to the results obtained from the safety test and hemagglutination assay, the optimum dose of virus inactivation was determined to be 28 kGy by maintaining the antigenic properties.
Conclusion Gamma radiation appears to be a good candidate for vaccine development through maintaining the antigenic structures.


Page 1 from 1     

© 2025 CC BY-NC 4.0 | Journal of Arak University of Medical Sciences

Designed & Developed by : Yektaweb